|
Market Closed -
Nasdaq
20:00:00 28/10/2026 GMT
|
5-day change | 1st Jan Change | ||
| 63.02 USD | +1.50% |
|
+0.16% | -17.04% |
| 10-15 | UBS Adjusts Price Target on PTC Therapeutics to $90 From $80, Maintains Buy Rating | MT |
| 10-08 | RBC Cuts Price Target on PTC Therapeutics to $75 From $85, Keeps Sector Perform Rating | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Pharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 5.18B | |||||
| 1,143B | |||||
| 647B | |||||
| 506B | |||||
| 384B | |||||
| 350B |
Select your edition
All financial news and data tailored to specific country editions
